News & Events
< Back to News Overview
KaloBios Collaborates to Engineer Human Antibody Therapeutic Drugs
31 / 05 / 2006
Successful completion of first HumaneeringT program and commencement of a broader agreement
KaloBios Pharmaceuticals Inc., a privately held biopharmaceutical company, today announced the successful completion of a project for the Genomics Institute of the Novartis Research Foundation (GNF) and Novartis to humaneerT an antibody against an undisclosed target. In exchange for creating this engineered human antibody therapeutic, KaloBios receives research and success fees, and can receive additional milestones and royalties upon successful completion of clinical trials. The companies also announced the commencement of a second broader agreement. Exact terms of either agreement were not disclosed.
Under the first agreement, GNF's high affinity and high potency non-human antibody drug candidate was humaneeredT by KaloBios. The humaneeredT antibody that KaloBios delivered met or exceeded all of the GNF- and Novartis-defined success criteria, triggering a success payment.
"We are happy that GNF and Novartis have identified KaloBios as a partner who can help as part of their antibody development engine. In turn, we are committed to helping GNF and Novartis make the best possible human antibody therapeutics," said Geoffrey Yarranton, PhD, CEO of KaloBios.
HumaneeringT is KaloBios Pharmaceutical's proprietary method for converting non-human antibodies into engineered human antibodies for therapeutic drug applications. The system has the advantage of maintaining epitope specificity and increasing affinity. The humaneeredT antibodies are as close as, if not closer to human germline sequences than the products of fully human antibody generation techniques. KaloBios is offering access to its humaneeringT capabilities on a limited basis.
KaloBios Pharmaceuticals Inc., a privately held biopharmaceutical company, today announced the successful completion of a project for the Genomics Institute of the Novartis Research Foundation (GNF) and Novartis to humaneerT an antibody against an undisclosed target. In exchange for creating this engineered human antibody therapeutic, KaloBios receives research and success fees, and can receive additional milestones and royalties upon successful completion of clinical trials. The companies also announced the commencement of a second broader agreement. Exact terms of either agreement were not disclosed.
Under the first agreement, GNF's high affinity and high potency non-human antibody drug candidate was humaneeredT by KaloBios. The humaneeredT antibody that KaloBios delivered met or exceeded all of the GNF- and Novartis-defined success criteria, triggering a success payment.
"We are happy that GNF and Novartis have identified KaloBios as a partner who can help as part of their antibody development engine. In turn, we are committed to helping GNF and Novartis make the best possible human antibody therapeutics," said Geoffrey Yarranton, PhD, CEO of KaloBios.
HumaneeringT is KaloBios Pharmaceutical's proprietary method for converting non-human antibodies into engineered human antibodies for therapeutic drug applications. The system has the advantage of maintaining epitope specificity and increasing affinity. The humaneeredT antibodies are as close as, if not closer to human germline sequences than the products of fully human antibody generation techniques. KaloBios is offering access to its humaneeringT capabilities on a limited basis.